28/07/2026 09:04 - Salud
Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) has officially simplified the way patients can obtain certain common medications. Through Disposition 4714/2026, published in the Official Gazette on July 28, 2026, the agency authorized the over-the-counter sale of ten active ingredients used for low-complexity conditions. The measure takes effect on July 29, 2026.
For international readers: ANMAT is the Argentine equivalent of the U.S. FDA or the European EMA. It regulates all medicines, food, and medical technology in the country. The term “over-the-counter” (OTC) means you can buy these drugs at any pharmacy without a doctor’s prescription.
The list includes oral, ophthalmic, and topical products for mild, easily recognizable symptoms:
By moving to OTC status, these drugs no longer require a prescription. However, there is a key financial impact: they will lose the mandatory discounts that social security (obras sociales) and private health insurance (prepagas) are required to provide for prescription drugs. In Argentina, most people have coverage through these systems, and prescription drugs are often heavily subsidized. Without a prescription, patients will pay the full retail price, though competition may keep prices in check.
Manufacturers must adapt new batches. After the effective date, packages must display the “Venta Libre” (OTC) label, include a QR code linking to the full package insert, and strictly follow authorized dosages and treatment durations.
ANMAT did not rush this decision. The agency required that each drug had been sold under prescription in Argentina for at least five years with no serious adverse event reports. It also looked at the experience of highly vigilant international health agencies that had already approved OTC sales: the FDA (United States), EMA (Europe), ANVISA (Brazil), and INVIMA (Colombia).
This process follows Resolution 284/2024 from Argentina’s Ministry of Health, which tasked ANMAT with reviewing dispensing conditions. A successful precedent was the OTC release of proton pump inhibitors (prazoles) in 2024, whose prices rose much less than general inflation, showing that the measure expands access without causing speculative distortions.
Alfredo S. Quiroga
